NOXAFIL

Generic: POSACONAZOLE

Merck Sharp & Dohme LLCManufacturer
ORALRoute
POSACONAZOLEActive Substance
2021-05-31Original Approval

NOXAFIL is FDA application NDA214770, sponsored by MSD MERCK CO. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Class II2025-12-12
Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufacture

Presence of particulate matter: potential presence of metal particulates in the product.

Top Reported Reactions

1
OFF LABEL USE
1,658 reports
2
DRUG INEFFECTIVE
1,480 reports
3
FEBRILE NEUTROPENIA
1,072 reports
4
DRUG INTERACTION
1,021 reports
5
PRODUCT USE IN UNAPPROVED INDICATION
1,008 reports
6
DEATH
976 reports
7
PYREXIA
890 reports
8
NEUTROPENIA
747 reports
9
PNEUMONIA
680 reports
10
THROMBOCYTOPENIA
537 reports